- Home
- LRMR vs CRDF Comparison
LRMR vs CRDF Comparison
Compare LRMR & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRMR
- CRDF
- Stock Information
- Founded
- LRMR N/A
- CRDF 1999
- Country
- LRMR United States
- CRDF United States
- Employees
- LRMR N/A
- CRDF N/A
- Industry
- LRMR Biotechnology: Pharmaceutical Preparations
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LRMR Health Care
- CRDF Health Care
- Exchange
- LRMR Nasdaq
- CRDF Nasdaq
- Market Cap
- LRMR 191.4M
- CRDF 210.2M
- IPO Year
- LRMR N/A
- CRDF N/A
- Fundamental
- Price
- LRMR $3.09
- CRDF $3.66
- Analyst Decision
- LRMR Strong Buy
- CRDF Strong Buy
- Analyst Count
- LRMR 7
- CRDF 5
- Target Price
- LRMR $17.86
- CRDF $10.50
- AVG Volume (30 Days)
- LRMR 1.4M
- CRDF 1.5M
- Earning Date
- LRMR 08-06-2025
- CRDF 08-07-2025
- Dividend Yield
- LRMR N/A
- CRDF N/A
- EPS Growth
- LRMR N/A
- CRDF N/A
- EPS
- LRMR N/A
- CRDF N/A
- Revenue
- LRMR N/A
- CRDF $587,000.00
- Revenue This Year
- LRMR N/A
- CRDF N/A
- Revenue Next Year
- LRMR N/A
- CRDF N/A
- P/E Ratio
- LRMR N/A
- CRDF N/A
- Revenue Growth
- LRMR N/A
- CRDF N/A
- 52 Week Low
- LRMR $1.61
- CRDF $2.01
- 52 Week High
- LRMR $11.20
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- LRMR 60.78
- CRDF 58.81
- Support Level
- LRMR $2.81
- CRDF $3.07
- Resistance Level
- LRMR $3.19
- CRDF $3.24
- Average True Range (ATR)
- LRMR 0.30
- CRDF 0.23
- MACD
- LRMR 0.01
- CRDF 0.00
- Stochastic Oscillator
- LRMR 82.43
- CRDF 67.96
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.